Skip to main content

Carbonic anhydrase IX in early-stage non-small cell lung cancer.

Publication ,  Journal Article
Kim, SJ; Rabbani, ZN; Vollmer, RT; Schreiber, E-G; Oosterwijk, E; Dewhirst, MW; Vujaskovic, Z; Kelley, MJ
Published in: Clin Cancer Res
December 1, 2004

PURPOSE: Tumor hypoxia is associated with poor prognosis and increased tumor aggressiveness. Carbonic anhydrase (CA) IX, an endogenous marker for tumor hypoxia, catalyzes the hydration of carbon dioxide into carbonic acid and contributes to the pH regulation of tumor cells. Therefore, CA IX might allow tumors to acclimate to a hypoxic microenvironment, promoting tumor cell proliferation. We hypothesized that CA IX expression is related to tumor cell proliferation and poor disease-free survival in patients with early-stage non-small-cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: CA IX expression was measured in 75 resected NSCLC tumors to assess prognostic implications for disease-free survival. The relationship of CA IX expression with microvessel density (MVD) and proliferation (Ki-67) index was assessed via colocalization analysis. RESULTS: All patients had operable NSCLC (stage I, 58; stage II, 17). CA IX expression was present in 54 (72%) of 75 patients and was associated with tumor necrosis (P < 0.05). CA IX-positive tumor areas showed greater cell proliferation as measured by Ki-67 index (P < 0.05) and less MVD (P < 0.05) than did CA IX-negative areas in colocalization analysis. The percentage of CA IX-positive tumor cells was significantly related to postoperative recurrence and poor disease-free survival (P < 0.05). Ki-67 index and pathologic stage were also independent prognostic factors for worse disease-free survival (P < 0.05). CONCLUSIONS: CA IX expression of tumor cells may be an indicator for poor disease-free survival in early-stage NSCLC.

Duke Scholars

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

December 1, 2004

Volume

10

Issue

23

Start / End Page

7925 / 7933

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Postoperative Period
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Microcirculation
  • Male
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kim, S. J., Rabbani, Z. N., Vollmer, R. T., Schreiber, E.-G., Oosterwijk, E., Dewhirst, M. W., … Kelley, M. J. (2004). Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res, 10(23), 7925–7933. https://doi.org/10.1158/1078-0432.CCR-04-0636
Kim, Seok Jin, Zahid N. Rabbani, Robin T. Vollmer, Ernst-Gilbert Schreiber, Egbert Oosterwijk, Mark W. Dewhirst, Zeljko Vujaskovic, and Michael J. Kelley. “Carbonic anhydrase IX in early-stage non-small cell lung cancer.Clin Cancer Res 10, no. 23 (December 1, 2004): 7925–33. https://doi.org/10.1158/1078-0432.CCR-04-0636.
Kim SJ, Rabbani ZN, Vollmer RT, Schreiber E-G, Oosterwijk E, Dewhirst MW, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res. 2004 Dec 1;10(23):7925–33.
Kim, Seok Jin, et al. “Carbonic anhydrase IX in early-stage non-small cell lung cancer.Clin Cancer Res, vol. 10, no. 23, Dec. 2004, pp. 7925–33. Pubmed, doi:10.1158/1078-0432.CCR-04-0636.
Kim SJ, Rabbani ZN, Vollmer RT, Schreiber E-G, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res. 2004 Dec 1;10(23):7925–7933.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

December 1, 2004

Volume

10

Issue

23

Start / End Page

7925 / 7933

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Postoperative Period
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Microcirculation
  • Male
  • Lung Neoplasms